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ABSTRACT 
Purpose.The aims of the present study were (i) to investigate the impact of great age on 
pharmacokinetics of capecitabine and its metabolites and (ii) to evaluate the exposure/effect 
relationship of capecitabine in elderly patients.Methods.Data collected from 20 elderly 
patients (75-92 years old) with breast or colorectal cancer, who received oral capecitabine 
were analyzed. In order to study the old age effect on pharmacokinetics, data collected from 
two phase I studies involving 40 younger adults (<75 years old) with metastatic cancer who 
received oral capecitabine, were added in the database. The population pharmacokinetic 
analysis was based on a four compartment model describing the sequence of capecitabine and 
three of its metabolites. Results.The absorption rate constant was found lower in the oldest 
patient group (≥75 y) compared to the youngest group, and the constant rate elimination of the 
5-fluorouracil metabolite was found decreased over time (i.e. after 2 consecutive weeks of 
capecitabine administration). This time effect was not found different between the two age 
groups. In elderly patients, the exposure-safety analysis showed, from the second cycle of 
chemotherapy, significantly higher median exposures of capecitabine and its metabolites (5’-
deoxy-5-fluorocytidine,5’-deoxy-5-fluorouridine and 5-fluorouracil) in patients who 
experienced hand-foot syndrome compared to patients who did not.Conclusion. This study 
puts forward new arguments for the treatment of elderly cancer patients who could benefit 
from capecitabinechemotherapy with acceptable toxicity. 
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INTRODUCTION 
Cancer is a major cause of death in developed countries, particularly in the elderly population. 
Most cancers occur after the age of 65. Colorectal and breast cancers are the most common 
cancers in the elderly population, in addition to prostate and lung cancers [1].The risk of 
colorectal cancer increases with age and the incidence is higher in the seventh and eighth 
decades of life [2]. Breast cancer is the leading cause of cancer mortality in women 
worldwide, and nearly a third of breast cancer cases occurs in patients aged over 65 years old 
[3].  
Despite the increasing risk of cancer in the elderly population, this age group is 
underrepresented in clinical trials [4,5]. Data on dose-concentration and dose-response 
relationships are therefore scant in such patients for whom the optimal treatment strategy is 
poorly defined so far. However, advancement of age is associated with significant 
physiological and morphological changes which may alter the different stages of the journey 
of a drug through the body: absorption, distribution, metabolism and elimination [6,7].         
Decline of renal function is common in the elderly [6,7], thus a significant change in the 
pharmacokinetics (PK) of drugs in this population is the reduction in renal elimination. 
Capecitabine, an oral prodrug of the cytototoxic agent 5-fluorouracil (5-FU), has 
demonstrated considerable single-agent activity in metastatic breast or colorectal cancers [8]. 
After oral administration, capecitabine is rapidly converted into 5’-deoxy-5-fluorocytidine 
(5’-DFCR) mainly in liver via hepatic carboxylesterase. 5’-DFCR is then metabolized to 5’-
deoxy-5-fluorouridine (5’-DFUR) via cytidinedeaminase, which is principally located in the 
liver and tumour tissues. Finally, 5’-DFUR is converted to the active cytotoxic agent 5-FU 
mainly via thymidine phosphorylase which is present at higher concentrations in tumour 
tissues [9]. 5-FU is further metabolized to an active phosphate analogue or is catabolized to 
alpha-fluoro-beta-alanine (FBAL) [10]. Capecitabine and its metabolites are mainly excreted 
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in urine [11];more than 70% of the administered dose is recovered in urine, of which 50 % as 
FBAL. 
The PK of capecitabine and its metabolites have been mainly described with non-
compartmental methods [12,13]. Population PK (popPK) modelswere developed to analyze 
the two sequences: 5’-DFUR>5-FU>FBAL [14] and capecitabine>5’-DFCR>5’-DFUR>5-FU 
[15]. 
In the elderly patients, some studies focused on efficacy/ safety responses or cognitive 
changes related to capecitabine[16–18]but few studies have investigated the PK of 
capecitabine. In most of these PK studies, the proportion of elderly patients (> 70 years) was 
very low (<10%) or null [10,15,19]. Louieet al[13]analyzed, with a non-
compartmentalmethod, the impact of age on capecitabine and itsmetabolites disposition using 
a greater proportion of elderly patients, but the verysmallnumber of patients in the younger 
group (5 patients <60 years vs 24 ≥70 years) was a limitation of the study. Therefore, new 
studies are needed to investigate the influence of great age on PK and systemic exposure of 
capecitabine and its metabolites. 
The present study aims (i) to report the results of the clinical trial CAPAGEC 
(NCT00812864) involving elderly patients with breast or colorectal cancer who received oral 
capecitabine, and (ii) to investigate the impact of age on PK of capecitabine and its 
metabolites. A secondary objective was to evaluate the response (tolerability and efficacy) of 
capecitabine in elderly patients, in particular with regard to the exposure/effect relationship. 
 
MATERIAL AND METHODS 
Patients and treatment 
The mono-center CAPAGEC trial recruited 20 patients aged 75 years or more with breast or 
colorectal cancer in the University Hospital of Limoges (France). The study complied with 
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legal requirements and the Declaration of Helsinki, and was approved by the regional Ethics 
Committee. Each patient had provided informed consent to participate in the study. Patients 
received 1250 mg/m
2 
of oral capecitabine twice daily for 14 consecutive days as anticancer 
monotherapy at each cycle. Cycles were repeated every 3 weeks (14 days treatment, 7days 
break) for a total of six cycles. Pharmacokinetic evaluations were performed on day 1 of cycle 
1 and day 14 of cycle 2. Blood samples were collected at pre-dose time and 0.5, 1, 1.5, 2, 4, 6 
and 8h after drug intake. Capecitabine, 5’-DFUR, 5-FU and FBAL concentrations were 
measured with two validated, specific, selective reverse-phase high performance liquid 
chromatography–tandem mass spectrometry methods in positive (capecitabine and 5’-DFUR) 
and negativeion modes (5-FU and FBAL), following two ionic transitions per compound. The 
calibration curves were linear from 77 nmol/L up to 7688 nmol/L (5-FU), 41 nmol/L to 20309 
nmol/L (5’-DFUR), 6 nmol/L to 27828 nmol/L (capecitabine) and 19 nmol/L to 93385 
nmol/L (FBAL). The within-day and between-day coefficients of variation and bias were less 
than 15% over these ranges.  
In order to study the old age effect on pharmacokinetics, data collected from two phase I 
studies including 40 younger adults (<75 years old) were added to the CAPAGEC database. 
The details of these two phase I studies were previously described elsewhere [15]. Briefly, 
patients had been diagnosed with metastatic cancer and were receiving second or third line 
chemotherapy. Capecitabine was orally administered every 12 hours at a dose of 1400, 1700, 
2000 or 2300 mg/m
2
/day and was combined to either irinotecan or to irofulven. For most 
patients, two pharmacokinetic evaluations took place on days 1 and 15.  
Population Pharmacokinetic analysis 
Concentration-time data of capecitabine and its metabolites were analyzed via a population 
approach using NONMEM® (version 7.2.0, ICON Development Solutions, Hanover, MD, 
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USA) [20]executed using Wings for NONMEM version 703 (developed by N. Holford, 
Auckland, New Zealand, available from http://wfn.sourceforge.net).  
As a basis for this work, we used the PK model developed by Urienet al[15]. This model 
included four compartments, the first one for capecitabine, the three following compartments 
describing the sequence of metabolites 5’-DFCR, 5’-DFUR, and 5-FU. The possibility to add 
a fifth compartment for the final metabolite FBAL was tested using the PK data collected in 
the CAPAGEC trial only (as FBAL concentration data were not available in the other 
patients) (Figure 1). Concentration data of the first metabolite, 5’-DFCR was available only 
for the patients enrolled in the two phase I studies and not for the patients included in the 
CAPAGEC trial. The first-order estimation method was used. Improvement of the model by 
inclusion of inter-subject and inter-occasion variabilities (ISV and IOV, 
respectively)described using an exponential error model was tested for all PK parameters. 
In a second step, the influence on PK parameters (apparent clearance -CL- and k terms) of age 
(coded either as continuous or categorical - <75 years group versus≥75 years group - 
covariate), gender, body weight, body surface area, clearance of creatinine calculated 
according to the Cockcroft and Gault formula [21], total bilirubin were examined. 
Additionally, to investigate the modification of pharmacokinetic parameters over time, the 
parameters were allowed to vary between the two pharmacokinetic evaluationsand this effect 
could be different between the two age groupsbecause (i) the day of the second PK evaluation 
was different for these two groupsand (ii) the chemotherapy protocols were 
different.Continuous covariates were investigated as shown in equation 1. Categorical 
covariates (gender, age group and day of PK evaluationwere tested using equation 2: 
Eq.1: P= θ1. (Cov/Covmedian)
θ2
 
Eq.2: P= θ1. θ2
Cov
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where P is the mean PK parameter (also called typical value) of interest, θ is the parameter 
estimate and Cov is the value of the covariate tested. 
The model was built stepwise[22]. A specific assumption was tested at each step. The relevant 
covariates were selected by taking into account the statistical significance, scientific 
plausibility and clinical relevance.  
The covariates were first tested in univariate analysis using forward inclusion to build-up the 
full covariate model. The final model was then developed by backward exclusion of 
covariates that were not significant. Differences in objective function values (∆OFV) were 
used for structural model selection and testing of covariates. The statistical significance was 
set to p<0.01 for the forward inclusion and p<0.001 for the backward exclusion.  
Internal evaluation of the population PK model 
The bootstrap resampling method [23] using 1000 samples was used for internal evaluation of 
the final model. Median and non-parametric 95% confidence interval based on the 2.5
th
-
97.5
th
percentiles were calculated on the bootstrap samples and compared to the final model 
parameters.The bootstrap procedure was performed using Wings for NONMEM. 
The final model was used to study the relationship between capecitabine AUC and dosage. 
Exposure-effect relationships 
The individual area under the concentration-time curve (AUC) values were obtained from the 
individualpharmacokinetic parameters provided by the POSTHOC option using the final 
population PK model. In case of the model failing to describe the PK of some metabolite(s), 
the observed trapezoidal AUC was taken into account.   
Toxicity and response data were available for the elderly patients only (i.e. patients included 
in the CAPAGEC trial).  
Toxicity was evaluated after each cycle of chemotherapy according to the National Cancer 
Institute common toxicity criteria. The dependent toxicity variables were defined as binary 
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(yes/no) variables and were identified in the analyses as grade 2-3 of hand–foot syndrome 
(HFS) and grade ≥ 2 of diarrhea. The AUCs of capecitabine and its metabolites at the first 
cycle of treatment were used to analyze the association with events which occurred between 
the two first cycles, and the exposures of the second cycle of treatment were used to analyze 
the association with events which occurred after the second cycle. Efficacy was measured at 
cycle 3 and cycle 6 using RECIST (Response Evaluation Criteria in Solid Tumors). These 
criteria are used in oncology studies to evaluate tumor burden and define when cancer patients 
improve (“respond”), stay the same (“stabilize”) or worsen (“progress”) in response to 
treatments. When disease progression occurred, the treatment was stopped. In the intent-to-
treat analysis of efficacy, patients were classified into 2 categories: (i) patients who were 
“stable” or with “response”; (ii) patients with treatment failure including clinical progression 
of the disease and disruption of the treatment because of severe toxicity, comorbidities, or 
decision of the patient to stop the treatment. The dependent efficacy variable was defined in 
the analysis as binary variable for “response or stable” (yes) and treatment failure (no). The 
relationships between exposures of capecitabine and its metabolites at the first cycle of 
treatment and the tumor response evaluated at cycle 3 and cycle 6 were investigated. 
Statistical analysis 
Quantitative variables were expressed as median (range). To compare the groups of patients 
included in the two phase I studies (≤73 years) and the patients included in CAPAGEC (≥75 
years) the Mann-Whitney non parametric test was used for continuous variables whereas the 
Chi square or exact Fisher test were used for categorical variables. Pearson correlation 
coefficient was used to study the dose/exposure relationship. Statistical analysis was 
performed using the MEDCALC 9.0 software (Medcalc Software, Mariakerke, Belgium). 
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RESULTS 
Patients  
The patients’ characteristics are summarized in Table I. A total of 20 patients (5 with breast 
cancer and 15 with colorectal cancer) with a median age of 80.5 years (range: 75-92) were 
enrolled in CAPAGEC. All were metastatic and had comprehensive geriatric assessment.Data 
on patient ethnicity were not available as collection of such data is not legal in France. 
In the CAPAGEC trial, 9 patients received the total of the 6 cycles of chemotherapy. The 
remaining 11 patients received 1 cycle (n=3), 2 cycles (n=3), 3 cycles (n=3) or 4 cycles (n=2).  
Population pharmacokinetic model 
A total of 2213 concentrationdata were analyzed (i.e. 584 for capecitabine, 354 for 5’-DFCR, 
577 for 5’-DFUR, 476 for 5-FU and 222 for FBAL).The model with the first 4 compartments 
adequately described the PK of capecitabine and three of its metabolites (5’-DFCR, 5’-DFUR, 
and 5-FU) in the studied population. The model including a fifth compartment for FBAL 
(concentrations available only in the 20 elderly patients) did not fit the FBAL data well. So 
the model with 4 compartments was retained. Introduction of ISV on tlag, V1, CL10, k23, k34 
and k40 and of IOV on ka significantly improved the fit of the model. So it was used to test 
covariate effect.  
In the univariate analysis,fivecovariates were selected: total bilirubin, body surface area, 
gender, day of pharmacokinetic evaluation(i.e. day 1 for all patients and day 15 in the <75 
years patients or cycle 2 day14 in the ≥ 75 years patients) and age group. Total bilirubin had a 
negative effect on k34(intercompartmental rate constant from 5’-DFCR to 5’-DFUR). The 
capecitabine absorption rate constant (ka) was lower in the ≥75 years patients group. The 
capecitabine apparent clearance (CL10) increased with body surface area and decreased with 
elapsed time, i.e. from the first to the second PK evaluation. The apparent clearanceCL12was 
lower inthe elderly population and at the second PK evaluation compared to the first 
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one.k40was lower in women than in men and also decreased over time. As a result of the 
forward inclusion and backward exclusion procedure, only the age group and the day of PK 
evaluationcovariateswere retained on ka and k40, respectively in the final model. Thereby, an 
OFV decrease of 50 units in comparison with the free-covariate model was obtained. The 
mean parameter estimates of the final model were similar to the median estimates resulting 
from the bootstrap procedure (Table 3).  
 
A significant positive linear correlation between predicted capecitabineAUC and administered 
dose was found in the elderly patients (≥ 75 years, r²=0.53, p<10-4) as well as in the younger 
patients. (r²= 0.41, p<10
-3
). These two coefficients were not significantly different (p=0.59). A 
similar correlation (r²=0.35) was observed between capecitabine AUC and administered dose 
expressed as mg/m² (from 1400 to 2300 mg/m²/day). 
Exposure-effect relationships 
Capecitabine administration had to be stopped before completion of the study in 11 patients 
because of disease progression (n=6, including one death), severe toxicities (n=2, one grade 3 
diarrhea and one grade 4 fatigue), comorbidities (n=1), patient’s decision to stop the treatment 
(n=1) and unknown reason (n=1). At the end of the treatment period, among the 9 patients 
who received the 6 cycles, 5 patients had stable disease, 1 patient was partial responder, 1 
patient had progressive disease and 2 patients had missing or insufficient response 
information (one of these two patients continued the treatment after the end of the clinical 
trial).  
Table 2 summarizes the treatment-related adverse events reported during the CAPAGEC trial. 
All the adverse events except one were in grade ≤3. Fatigue of grade 4 was reported in one 
patient leading to disruption of the treatment after the first cycle of treatment. The most 
frequently reported adverse events were HFS, fatigue and diarrhea, observed in 55%, 40% 
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and 30% of patients, respectively. Almost all the 21 HFS events were reversible, only one was 
persistent and the reversibility of two was not determined. Eighteen of the HFS events 
reported were grade 1 and grade 2. 
The exposure-effect relationshipswere studied in the elderly patients enrolled in CAPAGEC: 
20 patients for cycle 1, and 16 patients for cycle 2 (PK data were not available for 4 patients).  
The median AUCs of capecitabine and its metabolites were not statistically different between 
patients who experienced grade ≥ 2 of diarrhea and those who did not whatever the cycle of 
treatment (cycle 1 or 2). At the first cycle of treatment, only two patients experiences HFS 
(grade 1 and grade 2). These events did not seem associated with high AUC of capecitabine or 
of its metabolites. At cycle 2,AUCs of capecitabine, 5’-DFCR, 5’DFUR and 5-FU were 
significantly higher (p=0.01243 for capecitabine; p=0.03086 for 5’-DFCR; p=0.006392 for 
5’-DFUR and p=0.008967 for 5-FU) for patients who experienced HFS compared to those 
who did not. The difference was not statistically different (p=0.57) for the observed AUCs of 
FBAL (Figure 2). 
No difference in median AUCs of capecitabine and its metabolites obtained at cycle 1 was 
observed between “responders or stable” and “treatment-failure” patients. 
 
DISCUSSION 
In a population including one third of elderly patients (≥75 years), the capecitabine absorption 
rate constant was found lower in the oldest patient group, while the constant rate elimination 
of the 5-FU metabolite (k40) decreased significantly over time (i.e. after 2 consecutive weeks 
of capecitabine administration). 
Furthermore, from the second cycle of treatment, significantly higher median exposures of 
capecitabine and its metabolites (5’-DFCR, 5’-DFCR and 5-FU) were observed in patients 
who experienced HFScompared to those who did not.  
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The pharmacokinetics of capecitabine and its first three metabolites (5’-DFCR, 5’-DFCR and 
5-FU) were satisfactorily described by a four compartment model.The population 
pharmacokinetic analysis failed to describe FBAL concentrations, available for only 20 
patients over 60. The FBAL compartment was the last one in the tested five compartment 
model so no concentration downstream could help to describe the FBAL amounts eliminated. 
Herein, mean capecitabine absorption constant rate (ka) values of 1.86 and 0.84 h
-1
 (i.e. 
1.86*0.4) were obtained in the <75 years group and in the ≥75 years group, 
respectively.Interestingly, these two typical values of ka were close together and similar to 
those reported in other studies with mean age lower than 65 years old [10,15]. Thereby, it 
seemed difficult to discriminate between an age effect or a “study” effect. Of note, the 
schedule of capecitabine administration and the chemotherapy regimen (dosage and 
combination of chemotherapies)differed between the analyzed trials.Magnitude of this effect 
was rather small, so it could be ignored for individual dose adjustment. 
Elimination rate constant of 5-FU was found decreasedover time. This time effect was not 
found different between (i) the <75 years group for which the second PK evaluation took 
place after 15 days of treatment and (ii) the ≥75 years group for which the second PK 
evaluation took place on day 14 of cycle 2.This suggests an increase of 5-FU exposure after 
two weeks of treatment whatever the cycle of chemotherapy. A time-dependency was 
previously shown in continuous 5-FU infusion [22,24,25].  
In the univariate analysis, an association between BILT and k34 and between gender and 
elimination rate constant of 5-FU were also found, but this was not confirmed in the 
multivariate analysis. Similar conclusions were previously reported [15]. Interestingly, other 
studies reported gender effect on 5-FU elimination in populations receiving 5-FU 
chemotherapy [22,24].No effect of age was found on elimination parameters of capecitabine 
and its metabolites. In the present population analysis, the only effect of age was the 
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questionable relationship between age group and ka. This advocates for a negligible effect of 
great age which would not be associated with accumulation of capecitabine and its 
metabolites. It is noteworthy that the monograph of oral capecitabine claims that age does not 
affect the pharmacokinetic disposition of 5’-DFUR or 5-FU. 
Louie et al.[13] reported a significant increase in capecitabine AUC (p<0.05) associated with 
a reduction in capecitabine apparent clearance in elderly patients (≥70 years). The elderly 
group also presented lower estimated clearance of creatinine (CLCR, estimated with the 
Cockcroft and Gault formula) than the younger control group. However, this control group 
included only 5 patients aged less than 60 years. In the present study, CLCRwas not identified 
as a significant covariate in the population PK model for capecitabine, 5’DFCR, 5’DFUR and 
5-FU. These results were in accordance with those reported by Pooleet al.[26] and by 
Gieschkeet al.[10]who did not find significant relationship between CLCRand systemic 
exposure to capecitabine or 5-FU.   
This study confirmed a linear increase in capecitabine AUC with dosage increases, taking into 
account either the dose actually administered (in mg) or the dose level based on surface area 
(mg/m²) [12]. 
Five of the 20 elderly patients (25%) achieved stable disease and one patient (5%) was partial 
responder. Therefore, the response rate obtained was very encouraging in these old patients. A 
response rate of 20% (complete or partial responders) was previously reported in a population 
aged between 26 and 78 years with metastatic breast cancer and treated with a similar dose of 
capecitabine (2510 mg/m
2
/day of capecitabine) [27].  
Treatment-related adverse events reported in CAPAGEC were almost all in grade ≤3 and only 
two caused disruption of the treatment before completion of the study (diarrhea grade 3 and 
fatigue grade 4). HFS was the most frequently reported adverse event, in addition to diarrhea 
and fatigue. Fifty percent of patients (n=11) experienced HFSat least once over the study 
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period, and most of the HFS were rated as grade 1 or 2 in intensity. Out of these 11 patients, 6 
received the entire 6 cycles. Similar or higher frequencies of HFSwere reported in two studies 
performed in patients aged between 26 and 78 years [27], and between 25 and 79 years [28], 
and treated with similar doses of capecitabine than our study (2510 mg/m
2
/day and 2500 
mg/m
2
/day, respectively). In the first study, HFSoccurred in 56.2% of patients and most of 
them was graded as mild or moderate (grade 1 or 2) [27]. In the second study, the proportion 
of patients with HFSwas 68.3%, with most of them occurring within the two first cycles and 
classed as grade 1 or 2 [28]. Thus, elderly patients did not seem to present any more HFS 
toxicity than the general population. 
In CAPAGEC, the median AUCs of capecitabine, 5’-DFCR, 5’-DFUR and 5-FU (but not 
FBAL) observed at the last day of the second cycle of treatment were found to be 
significantly higher in patients who experienced grade 2-3 of HFS compared to those who did 
not. Interestingly, it was previously reported that both peak drug concentration and total 
cumulative dose determine HFS occurrence [28]. However, in a large population dataset 
(n=481 patients) Gieschkeet al.[10]found no relationship between grade 3 of HFS andCmaxor 
AUC of 5’DFUR, 5-FU and FBAL. The exposure-efficacy analysis performed in the current 
study did not find a significant difference in the median AUC of capecitabine and its 
metabolites at the first cycle between “responders or stable” and “treatment-failure” patients. 
Similarly, Cmax and AUC of capecitabine and its metabolites were found poorly predictive of 
efficacy variables, defined as tumor response/non response, time to disease progression and 
duration of survival[10].Only AUCs measured at the first cycle only were taken into account 
in this latter analysis. Of note, for docetaxel, a significant relationship was showed between 
first course AUC and time to progression, in non-small-cell-lung-cancer [30]. 
In conclusion, the current study has not demonstrated a majoreffect of great age on 
pharmacokinetics of capecitabine and its metabolites. 5-FU constant rate elimination was 
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found decreased over time, but this effect was similar before and after 75 years old. 
Additionallyno major difference in treatment tolerability and response rate in elderly patients 
as compared to reported data in younger subjectshas been observed. This study puts forward 
therefore new arguments for the treatment of elderly cancer patients who could benefit from 
capecitabinechemotherapy.Additionally, the present exposure-effect analysis showeda 
relationship between exposure of capecitabine and some of its metabolites (5’-DFCR, 5’-
DFUR and 5-FU) and the onset of hand-foot syndrome. Further studies with a larger number 
of elderly patients may be needed to confirm these results. 
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LEGEND OF FIGURES 
 
Figure 1: Compartmental model describing the pharmacokinetics of capecitabine and its four 
metabolites.  
Abbreviations: ka: absorption rate constant; tlag: lag-time; V1: apparent distribution volume of 
capecitabine; CL10 and CL12: apparent capecitabine clearances; k23:intercompartmental rate 
constant of 5’-DFCR;k34:intercompartmental rate constant of 5’-DFUR; k45: 
intercompartmental rate constant of 5-FU; k50: elimination rate constant of FBAL. 
*These two metabolites were measured only in one subgroup of patients; 5’-DFCR was 
measured only in patients of the two phase I study (<75years) and FBAL was measured only 
in patients of the CAPAGEC trial (≥75 years).  
 
 
Figure 2: Comparisons of the area under the concentration-time curve (AUC; µmol.h/L) of 
(a) capecitabine, (b) 5’DFCR , (c)5’DFUR,(d) 5 FU and (e) FBAL in the second cycle of 
treatment, between patients who experienced hand-foot syndrome (HFS+) and who did not 
experience (HFS-). 
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Table 1: Characteristics of the pharmacokinetic study population 
 
 
Characteristics Patients of the two phase I 
studies 
median [range] 
Patients of CAPAGEC 
median [range] 
P 
Number of patients 40 20  
Gender (Female/Male) 15/25 12/8 0.098 
Age (years) 54.5 [30-73] 80.5 [75-92] 3. 10
-10 
Body weight (kg) 68 [41-95] 74 [48-113] 0.055 
Body surface area (m
2
) 
1.80 [1.40-2.10] 1.82 [1.41-2] 0.52 
Total Bilirubin (μmol/L) 8.8 [3-22] 5.1 [2-13.3] 0.001 
ClCR(ml/min) 71 [28-115] 66 [23-137] 0.13 
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Table 2: Summary of the most common reported treatment-related adverse events in the 
CAPAGEC trial 
 
 
  
 Number of 
adverse events  
Number of 
patients (%) 
Grade of 
events 
Non hematologic adverse event 
   Hand-foot syndrome 
   Diarrhea 
   Fatigue 
   Nausea 
   Vomiting 
   Abdominal pain 
Mucositis 
Dysgeusia 
   Paresthesia 
   Anorexia 
 
21  
9 
8 
4 
3 
3 
3 
2 
3 
1  
 
11 (55) 
6 (30) 
8 (40) 
4 (20) 
3 (15) 
3 (15) 
2 (10) 
2 (10) 
1 (5) 
1 (5) 
 
1, 2, 3 
1, 2, 3 
1, 2, 3, 4 
1, 2 
1, 2 
1, 2 
1, 3 
1 
2, 3 
2 
Hematologic adverse event 
   Anemia 
   Neutropenia 
Thrombopenia 
 
 
5  
1 
3 
 
3 (15) 
1 (5) 
1 (5) 
 
1, 2, 3 
1 
1, 2 
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Table 3: Population PK parameters of capecitabine and bootstrap results 
 
Parameter Final model 
estimate 
(SD%) 
Bootstrapresults (n=1000 samples) 
Median 2.5th – 97.5th percentiles 
ka (h
-1
) = θ1. θ2
agegroup* 
θ1 
θ2   
 
1.86 (6.0) 
0.45 (11.2) 
 
1.94 
0.53 
 
0.72 – 2.57 
0.31 – 2.42 
tlag (h) 0.31 (4.5) 0.31 0.17 – 0.39 
V1 (L) 292 (9.2) 276 117 – 358 
CL10 (L/h) 214 (8.2) 220 186 – 264 
CL12 (L/h) 13.6 (10.5) 13.0 9.3 – 18.3 
k23(h
-1
) 10.9 (8.9) 10.5 7.6 – 13.9 
k34 (h
-1
) 6.0(10.6) 5.6 4.0 – 7.9 
k40(h
-1
)=θ3.θ4
day**
 
θ3 
θ4   
 
77.1 (11.9) 
0.77 (4.4) 
 
76.8 
0.81 
 
47.2 – 84.8 
0.56 – 1.15 
IOV ka (%) 129 (36) 134 78 – 213 
ISV tlag (%) 148 (38) 138 55 – 291 
ISV V1 (%) 107 (44) 112 79 – 176 
ISV CL10 (%) 27 (97) 28 12 – 44 
ISV k23 (%) 49 (51) 49 28 – 72 
ISV k34 (%)  35 (69) 33 20 – 47 
ISV k40 (%) 45 (60) 45 24 – 60 
Residualvariabilities (SD)    
Capecitabine(µM) 5.2 (3.7) 5.0 3.2 – 7.2 
5’ DFCR (µM) 3.7 (16.9) 3.6 2.6 – 4.5 
5’ DFUR (µM) 6.1(6.2) 5.8 4.7 – 6.9 
5 FU (µM) 0.7(7.2) 0.7 0.5 – 0.9 
 
Abbreviations: ka: absorption rate constant; V1: apparent distribution volume of capecitabine; 
tlag: lag time; k23:intercompartmental rate constant of 5’-DFCR; k34:intercompartmental rate 
constant of 5’-DFUR; k40: elimination rate constant of 5-FU;CL10 and CL12: apparent 
capecitabine clearances; ISV:intersubject variability; IOV: inter-occasion variability; 
SD:standard deviation. 
* agegroup=0 for <75 years patients and 1 for ≥75 years patients 
**day=0 for first administration of capecitabine) and day=1 for both the 15
th
 day of treatment 
and the14
th
day of treatment of cycle 2 
